INHIBRX BIOSCIENCES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.3M | $200.0K | $1.8M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $113.0M | $203.7M | $191.6M |
| SG&A Expense | $23.3M | $127.9M | $29.4M |
| Operating Income | $-135.0M | $-331.4M | $-219.2M |
| Operating Margin | -10,386.5% | -165,724.0% | -12,178.9% |
| Interest Expense | — | — | — |
| Pretax Income | $-140.1M | $1.69B | $-239.7M |
| Income Tax Expense | $2.0K | $2.0K | $3.0K |
| Net Income | $-140.1M | $1.69B | $-241.4M |
| Net Margin | -10,773.5% | 843,786.0% | -13,408.9% |
| EPS (Basic) | $-9.04 | $114.01 | $-20.48 |
| EPS (Diluted) | $-9.04 | $112.62 | $-20.48 |
| Shares Outstanding (Basic) | 15.5M | 14.8M | 11.8M |
| Shares Outstanding (Diluted) | 15.5M | 15.0M | 11.8M |
| Dividends Per Share | — | — | — |